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a  b  s  t  r  a  c  t
Objective:  The  purpose  of  the  present  study  was  to examine  the  motivations  underlying  the  use  of
buprenorphine  outside  of  therapeutic  channels  and the factors  that might  account  for  the reported  rapid
increase  in  buprenorphine  misuse  in  recent  years.
Methods:  This  study  used:  (1)  a mixed  methods  approach  consisting  of  a  structured,  self-administered
survey  (N = 10,568)  and  reflexive,  qualitative  interviews  (N = 208)  among  patients  entering  substance
abuse  treatment  programs  for opioid  dependence  across  the  country,  centered  on  opioid  misuse  patterns
and related  behaviors;  and (2) interviews  with  30 law  enforcement  agencies  nationwide  about  primary
diverted  drugs  in  their  jurisdictions.
Results:  Our results  demonstrate  that  the misuse  of  buprenorphine  has increased  substantially  in  the
last  5  years,  particularly  amongst  past  month  heroin  users.  Our  quantitative  and  qualitative  data  suggest
that  the  recent  increases  in buprenorphine  misuse  are  due  primarily  to the  fact  that  it  serves  a  variety
of  functions  for  the  opioid-abusing  population:  to get  high,  manage  withdrawal  sickness,  as  a  substitute
for  more  preferred  drugs,  to  treat  pain,  manage  psychiatric  issues  and  as a self-directed  effort  to  wean
themselves  off  opioids.
Conclusion: The  non-therapeutic  use  of  buprenorphinehas  risen  dramatically  in  the past  five  years,  par-
ticularly  in  those  who  also  use heroin.  However,  it  appears  that  buprenorphine  is rarely  preferred  for its
inherent  euphorigenic  properties,  but rather  serves  as  a substitute  for other  drugs,  particularly  heroin,
or as  a drug  used,  preferable  to methadone,  to  self-medicate  withdrawal  sickness  or  wean  off opioids.
©  2014 Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
Buprenorphine is a dose-dependent, mixed opioid ago-
nist/antagonist with very high affinity for the mu-opioid receptor,
but with limited intrinsic activity compared to other, more com-
monly used opioid analgesics (Walsh et al., 1994). Moreover, it has
a very low dissociation constant from the opioid receptor, generat-
ing a very long half-life and limiting dosing frequency (Bickel et al.,
1988; Donaher and Welsh, 2006; Greenwald et al., 2003). These
properties have made this drug a particularly attractive agent for
opioid substitution therapy programs across the world (Donaher
and Welsh, 2006; Johnson et al., 1992; Ling et al., 1998; Fiellin
and O’Connor, 2002; Degenhardt et al., 2009; Bell et al., 2009;
Sullivan et al., 2008; Alford et al., 2011). While it is maintained that
these programs have been successful in reducing use of illicit opi-
oids, buprenorphine itself has become a leading drug of choice for
∗ Corresponding author. Tel.: +1 314 362 4516; fax: +1 314 362 5630.
E-mail address: Cicerot@wustl.edu (T.J. Cicero).
non-therapeutic purposes (e.g., produce euphoria/get high) in
many countries which have such programs (Bell, 2010; Auriacombe
et al., 2004; Carrieri et al., 2006; Aalto et al., 2007; Yokell et al., 2011;
Guichard et al., 2003; Vidal-Trecan et al., 2003; Lavonas et al., 2014).
Recognizing this fact, the manufacturer reformulated buprenor-
phine with low doses of naloxone prior to its release in the United
States for opioid treatment (Reckitt Benckiser Pharmaceuticals
Inc., 2014). It was assumed that naloxone would antagonize the
euphoric properties of buprenorphine, or precipitate withdrawal
in opioid tolerant individuals (Chiang et al., 2003; Mendelson and
Jones, 2003; Walsh and Eissenberg, 2003; Stoller et al., 2001).Thus,
its risk of misuse was  considered to be quite low (Mammen and Bell,
2009; Alho et al., 2007; Comer et al., 2010; Schuster, 2006). Based
on early assessments of the drug, the Food and Drug Administration
not only approved buprenorphine and buprenorphine/naloxone as
part of comprehensive opioid harm reduction program in 2002,
but there was  sufficient confidence with these drugs that they were
approved to be prescribed for home use rather than made available
only in stand-alone methadone clinics, which are inconvenient,
carry a significant social stigma, and use an inherently less safe
http://dx.doi.org/10.1016/j.drugalcdep.2014.06.005
0376-8716/© 2014 Elsevier Ireland Ltd. All rights reserved.
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opioid (methadone) with significant adverse side-effects (Peterson
et al., 2010; Schwartz et al., 2008; Zaller et al., 2009). However, given
the experience in Europe, the FDA was cautious in its approach,
requiring specialized training and limitations of 30 buprenorphine
patients at one time for physicians (Substance Abuse and Mental
Health Services Administration (SAMHSA), 2014; Drug Addiction
Treatment Act of, 2000; Center for Substance Abuse Treatment
(CSAT), 2004). With the early apparent success of these programs,
restrictions were lifted in 2006 such that up to 100 patients could
be treated by an individual physician. Additionally, the introduc-
tion of less expensive generics in 2009 further contributed to large
increases in buprenorphine prescriptions in the past five years
(Drug Enforcement Administration, 2009). As expected from ear-
lier work showing a direct link between the extent of therapeutic
exposure and diversion for non-therapeutic purposes (Cicero et al.,
2007a,b), there have been reports of an increase in the diversion
and misuse of buprenorphine (Drug Enforcement Administration,
2009; Substance Abuse and Mental Health Services Administration
and Drug Abuse Warning Network (DAWN), 2011; United States
Department of Justice and National Drug Intelligence Center (NDIC),
2011; Wish et al., 2012).
The purpose of the present study was to examine multiple fac-
tors that might account for the rapid increase in buprenorphine
misuse in recent years and the motivations underlying the use of
buprenorphine outside of therapeutic channels. To address this
issue, we used a mixed methods approach utilizing data from
structured, self-administered surveys(N = 10,568) and reflexive,
qualitative interviews (N = 208) among patients entering substance
abuse treatment programs across the U.S. with a primary (DSM-
IV) diagnosis of opioid dependence. To assess diversion, data were
analyzed from semi-structured interviews among a sample of drug-
diversion law enforcement units across the country (N = 30).
2. Methods
This report utilized data from the Researched Abuse, Diversion and Addiction-
Related Surveillance (RADARS®) System, a comprehensive series of programs that
collect and analyze post-marketing data on the misuse and diversion of prescription
opioid analgesics and heroin (Cicero et al., 2007a,b).
2.1. Study Sample 1: SKIP
The Survey of Key Informants’ Patients (SKIP) Program consists of over 150
public and privately funded treatment centers (Key Informants), balanced geograph-
ically with coverage in 48 states, that recruit patients/clients entering treatment to
complete an anonymous survey centered on opioid misuse patterns and related
behaviors. Subjects must be 18 years or older and meet DSM-IV criteria for sub-
stance abuse with a primary drug that is an opioid (prescription or heroin). Surveys,
received on a rolling basis throughout the analyzed period, were identified by a
unique case number and sent directly to Washington University in St. Louis (WUSTL)
by  the respondent. Participants were compensated with a $20 Wal-Mart gift card.
Surveys were categorized by half-year and quarter, with SKIP data for this study
analyzed from January 1st, 2008 to September 30th, 2013.
2.2. Study Sample 2: RAPID
To supplement and add context to the structured SKIP survey, a sub-set of
patients indicated, by a mail-in postcard provided with the SKIP survey, their
willingness to give up their anonymity and participate in an unstructured interview-
based study, dubbed Researchers and Participants Interacting Directly (RAPID).
During the fourth quarter of 2013, 208 treatment clients consented to participate
in a self-administered internet questionnaire via SurveyMonkey. Those participants
who  indicated prior experience with buprenorphine were re-contacted to further
describe their opinions and experiences with buprenorphine N = (106). All partic-
ipants in the RAPID program were compensated with a $20 Wal-Martgift card.
Study protocols for the SKIP and RAPID programs were approved by the WUSTL
institutional review board.
2.3. Study Sample 3: Drug diversion
The Drug Diversion program of the RADARS® System collects data from a
national sample of law enforcement and regulatory agencies with agents assigned
to  prescription drug diversion investigations. The program includes approximately
260 investigators in 49 states. For this study, thirty investigators participating in the
Drug Diversion program in the second quarter of 2013 were randomly selected to
participate in a one-time, semi-structured telephone interview. These investigators
represented 23 states and were asked general questions about their units, caseload
information, primary sources of diversion and primary diverted drugs in their juris-
dictions. The study was deemed exempt by the institutional review board at Nova
Southeastern University.
2.4. Data analysis
Both SKIP and RAPID programs gather socio-demographic variables (e.g., sex,
current age and race/ethnicity). In addition, SKIP and RAPID participants identified
their primary drug (e.g., the drug used to get high most frequently in the month
prior to treatment), with SKIP respondents asked to also identify all opioid com-
pounds used to get high in the month prior to treatment stratified by formulation
and product, including whether or not each product was injected. “Misuse” is used
throughout this report to reference both non-therapeutic use and use outside of
legal  therapeutic channels. Except where noted, SKIP analyses included the entire
sample of both heroin and prescription opioid users due to the fact that there was
high concurrent use of both drugs; 85% of heroin users also indicated the past month
misuse of prescription opioids.
RAPID interview responses to the question “Please briefly explain in your own
words the reasons you took buprenorphine or how buprenorphine affected you,”
were dual-reviewed, and using the principles of thematic analysis, 13 motiva-
tions for using buprenorphine were identified. In order to get a more accurate
account of the variability in other buprenorphine-related motivations, a series of
true/false questions was developed based on eleven identified motivations, with “to
get  high” and “to treat/prevent withdrawal sickness” excluded because they were
asked directly through other SKIP and RAPID questions. Other RAPID data reported
in  this study were based on direct questions, with participants asked to explain their
responses in an open-ended format.
The Drug Diversion program analyzed the responses of law enforcement inves-
tigators interviewed about the most commonly diverted prescription drugs in their
area. In addition to identifying specific drugs, a review of the interview responses
led to the identification of other topics of interest. Topics noted by at least three
interviewees were then developed into themes and the presence of a theme (Y/N)
was coded back to the interviews. Qualitative data from the Drug Diversion and
RAPID programs were reviewed and coded using NVivo version 9. Quantitative data
in  both SKIP and RAPID datasets were analyzed using IBM SPSS Statistics v21.
3. Results
3.1. Demographics
Table 1 summarizes the gross demographic features of
those participating in the SKIP (N = 10,568; mean N per quar-
ter = 449.1 ± 36.6 SE) and RAPID (N = 208) programs. As can be seen,
the RAPID subset, though much smaller, was quite similar to the
larger SKIP sample. The majority of respondents were white and in
Table 1
Comparison of SKIP and RAPID demographic data.
SKIP1 (n = 10,568) RAPID2 (n = 208)
Gender
Male 50.4 48.4
Average age (±SEM) 34.2 ± 0.11 34.9 ± 0.81
Race/ethnicity
White 78.4 86.4
African American 9.0 4.3
Latino 4.9 3.7
Other 7.7 5.6
Primary drug
Buprenorphine 1.6 0.7
Fentanyl 1.0 2.0
Heroin 29.8 36.2
Hydrocodone 19.7 20.4
Hydromorphone 3.8 1.3
Methadone 5.6 2.0
Morphine 4.0 3.3
Oxycodone 32.4 29.6
Oxymorphone 1.1 1.3
Tapentadol 0.0 0.0
Tramadol 1.1 3.3
1 Data collected from January 1, 2008–September 30, 2013.
2 Data collected from October 1, 2013–December 31, 2013.
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Fig. 1. The percent (95% CI) of the total SKIP sample (A) who used buprenorphine in the past month to get high as a function of half-year intervals from 2008 to the end of
2013.  The year following the release of generics (dashed lines) is expressed in quarter-year intervals to emphasize the steepness in the rate of increase; (B) shows the misuse
(95%  CI) of buprenorphine in those SKIP respondents who used other prescription opioids to get high versus those who used other prescription opioids and heroin. Due to
the  fact that 85% of heroin users also used prescription opioids, the Ns for those using only heroin were too small (<35) for meaningful analysis.
their early thirties at the time of survey completion, with an even
distribution of males and females. Heroin and oxycodone were the
most popular primary drugs (i.e., the drug used most often in the
past month) in both groups, with buprenorphine one of the least
preferred.
3.2. Buprenorphine misuse
Although buprenorphine was endorsed as a primary drug by
less than 2 percent of each sample (Table 1), as shown in Fig. 1A
the number of SKIP respondents who indicated past month use
of buprenorphine to get high was much higher and the rate
almost quadrupled from 2008 to 2013. Most notably, there was
a steep increase in every quarter of 2010 (detailed in Fig. 1A),
the year following the introduction of buprenorphine generics in
2009. Data from law enforcement agents charged with investigat-
ing pharmaceutical diversion also indicated that buprenorphine
was a significant problem in 2013. It was the fourth most com-
monly diverted prescription drug as determined by case reports;
oxycodone was mentioned by 96.7% of respondents, followed by
hydrocodone (80%), alprazolam (57%), buprenorphine (33%) and
methadone (30%).
3.3. Heroin
As shown in Fig. 1B, those respondents who used both heroin
and other prescription opioids to get high in the past month also
misused buprenorphine at rates twice that reported by those only
using prescription opioids. Moreover, as shown in Fig. 2A, increases
in heroin use paralleled the increase in buprenorphine misuse,
most notably in the years following the introduction of a tamper-
resistant formulation of OxyContin® in the second half of 2010.
Forty percent of drug diversion investigators (N = 12) also noted a
parallel increase in heroin and buprenorphine use:
We’ve seen an increase in heroin and suboxone, they are
often packaged together. Suboxone is being prescribed in huge
amounts, this girl had 24 refills on her and she was dealing . . .we
arrested her shooting up in a restaurant.
3.4. Methadone
As shown in Fig. 2B, as the past month misuse of buprenorphine
increased over time, methadone misuse declined, such that, two
years after the introduction of buprenorphine generics, methadone
was less commonly misused than buprenorphine. In this context,
Fig. 2. The percent(95% CI) of the total SKIP sample that used buprenorphine, OxyContin® and/or heroin to get high in the past month plotted as a function of half-year
intervals from 2008 to 2013 (A); (B) shows the percent (95% CI) of the total SKIP sample that used buprenorphine and/or methadone to get high in the past month. The
introduction of an abuse deterrent formulation of OxyContin® is denoted by the dashed vertical line.
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Fig. 3. Buprenorphine product formulations used by SKIP respondents indicating any past month use of buprenorphine to get high plotted as a function of quarter-year inter-
vals  (95% CI) (A); (B) shows the total percentage of buprenorphine product formulations injected by SKIP respondents indicating any past month injection of buprenorphine
to  get high.
40% of respondents in the RAPID interviews indicated they had used
both buprenorphine and methadone for the purpose of treating or
preventing withdrawal sickness, either under a doctor’s care or on
their own initiative as a self-directed pharmacotherapy for opioid
dependence. When asked which drug they preferred, 61.5% chose
buprenorphine compared to just 25.6% favoring methadone (9.3%
had no preference). Reasons given for the preference of buprenor-
phine included “lasts longer”, “methadone is worse to come off of,”
and “does not get me  high”. As one respondent noted:
Methadone made me  feel high just like the meds I was trying
to come off of where the suboxone just makes me  feel normal.
On methadone I wanted to sleep all the time and the suboxone
I don’t. Also I felt the methadone clinics were legal drug dealers
who didn’t care about anything but the money I was  paying
them. My  suboxone doctor actually cares about me  and how
I’m doing in my  recovery and what’s going on in my  life.
Our data also indicate that lack of access to a buprenorphine
treatment program could be an important factor in the unsu-
pervised use of buprenorphine to treat opioid dependence. For
example:
Before I started my  treatment program I had a friend get a script,
he sold me  a couple [buprenorphine] to try and see if they would
ease my  withdraw. They did, so the next day I called his doctor
and tried to get an appointment, the wait was over a month.
I ended up going into a traditional treatment program about
a week later where they tried to just control the symptoms
and it was hell for more than 2 weeks before I finally called
the suboxone doc back and basically begged my  way  in their
office.
3.5. Buprenorphine formulations
Fig. 3A shows the misuse of buprenorphine subdivided by
formulation type. In the first quarter of 2010 (the earliest
date for which data were available), Suboxone® (buprenor-
phine + naloxone) tablets were the overwhelming choice, with over
90% of buprenorphine users in the past month selecting them.
Coincident with the discontinuation of the combination tablet and
the introduction of the combination oral film, misuse of the tablet
decreased and the misuse of the oral film increased sharply. Very
substantial increases in single ingredient (e.g., subutex) tablets mis-
use also occurred. Buprenorphine patches and solutions were rarely
endorsed as drugs of misuse.
3.6. Intravenous injection of buprenorphine
Over one-third (34.4%, n = 461) of buprenorphine misusers in
the SKIP sample indicated they had injected it in the month
prior to treatment. This was  particularly prevalent in those mis-
using both prescription opioids and heroin: 71.1% of those who
injected buprenorphine had also used heroin in the past 30 days.
As shown in Fig. 3B, single ingredient tablets were the most com-
monly injected (61.8%), but a surprisingly high number injected the
buprenorphine + naloxone tablet (43.6%) or oral film (32.1%). Given
that naloxone should have antagonized the euphorigenic effects
of buprenorphine, providing a low quality high, we  asked RAPID
participants how they circumvented the barriers of this formula-
tion. Participants reported a number of simple and easy methods,
unethical to specify in this paper, which they believed separated
buprenorphine from naloxone, resulting in what they termed “pure
buprenorphine” for injection.
3.7. Other motivations for buprenorphine use
Nearly 70% of RAPID follow-up participants indicated that they
had used buprenorphine, for any reason, at some point in the past.
As shown in the response to the True–False questions in Table 2,
very few individuals indicated that they used buprenorphine
Table 2
Motivations for prior buprenorphine use outside of a treatment program.
RAPID
(n = 106)
“I have used Buprenorphine at least once. . ..”
Because it gives me a better high than other
prescription opioid drugs
2.9
Because it was my drug of choice to get high with 3.9
To  maintain my  abstinence from other drugs 62.9
Because I was  trying to wean myself off drugs on my
own
54.8
To hold me  over during work/social events 52.9
Because I knew I would not have access to other
drugs for a period of time
59.6
Because it was cheaper than other drugs 15.4
Because my  drug of choice to get high with was not
available
60.4
Because it was the only drug that was available 53.9
To  treat my bodily pain when other drugs were
unavailable
50.0
Because it helped treat anxiety, depression or other
psychological symptoms
33.0
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because it produced a better high than other opioids. These data
are consistent with our observations in the much larger SKIP sam-
ple where very few individuals listed buprenorphine as their drug
of choice (Table 1). The primary reasons given for using buprenor-
phine seem to be divisible into two main categories: (1) use
of buprenorphine for the express purpose of treating/preventing
withdrawal sickness; and (2) as a substitute to get high when
other, more preferred drugs were unavailable (Table 2). Several
responses to our open-ended question asking why participants
used buprenorphine illustrate these often interrelated points:
When I first took [buprenorphine] I was mainly shooting heroin
. . . and then used subutex to keep me  from getting sick until I’d
use again. Sure the thought of actually using it to get off heroin
crossed my  mind but I began to use it to get high as well.
I have taken buprenorphine in the past to wean off heroin, both
under and not under the care of a physician. I also used it when
actively using to keep from getting sick if I did not have enough
heroin, and as a substitute.
3.8. Co-morbidity and buprenorphine use
A somewhat surprising finding was that 50% of buprenorphine
users indicated treating pain was one of the many reasons for
using it (Table 2). A third of the sample also indicated they used
buprenorphine to help with psychiatric problems. These points are
underscored by the following quotes:
I  had some left over from my  doctor (who I was no longer seeing)
and had some horrific pain in my  back that my  Norco didn’t
touch so I decided to go back and use Suboxone.
To get high, to get off opioid, to control physical pain, to numb
emotional pain, to avoid withdrawal, to avoid facing life without
the safety of a fog, to make uncomfortable situations tolerable,
to make unsafe situations feel safe, I used it just like I used
opioid–to face a reality I had no idea how to live in.
4. Discussion
Our results demonstrate that the misuse of buprenorphine
has increased substantially in the last 5 years, confirming and
extending earlier reports of such increases (Drug Enforcement
Administration, 2009; Substance Abuse and Mental Health Services
Administration and Drug Abuse Warning Network (DAWN), 2011;
United States Department of Justice and National Drug Intelligence
Center (NDIC), 2011; Wish et al., 2012; Lavonas et al., 2014). Cer-
tainly, much of this increase has been fueled by an increase in the
therapeutic use of buprenorphine, which was accelerated by the
release of generics in 2009. Given that it has been shown that there
is a direct correlation between the extent of therapeutic use and
diversion to street use (Cicero et al., 2007a,b; Lavonas et al., 2014),
increases in buprenorphine misuse are not unexpected. However,
our quantitative and qualitative data suggest that another major
reason buprenorphine misuse has increased in recent years is due
to the fact that it serves a variety of functions for the opioid-abusing
population: to get high, manage withdrawal sickness, as a substi-
tute for more preferred drugs, to treat pain, manage psychiatric
issues (i.e., depression and anxiety) and as a self-directed treat-
ment to wean off other misused opioids. This is especially evident
when viewed in the context of the rise in heroin use in the same
time frame which, at least in part, seems to be related to the intro-
duction of an abuse-deterrent formulation of OxyContin®. While
this greatly reduced OxyContin’s popularity as a drug of abuse, it
appears to have been followed by a concomitant increase in both
heroin and buprenorphine use. The reasons buprenorphine misuse
has increased so sharply in the past five years, particularly among
heroin users, are not fully understood, but may  be reflective of three
factors.
First, while it is clear that buprenorphine was very rarely the
drug of choice, our data indicate that it was an acceptable alterna-
tive for getting high when more preferred drugs were unavailable
(e.g., cost, lack of supply), particularly in intravenous injection drug
users.
Second, aside from the use of buprenorphine to get high, its long
half-life makes it ideal to ward off opioid withdrawal sickness until
preferred drugs are available or a as a self-directed treatment to
detox and wean off opioids.
Self-medication, rather than entry into a treatment program,
may  be related to lack of access or cost of these programs. In
this context, our study participants preferred buprenorphine to
methadone by more than a 2:1 margin when asked specifically
about its efficacy in treating withdrawal sickness. Given that
methadone is readily available on the street, access is unlikely to be
a factor. Rather it would appear that methadone has more undesir-
able properties such as side effects, social stigma associated with
stand-along treatment clinics and difficulty in weaning off it.
Finally, our data also suggest that pain management and self-
medication of serious psychiatric problems are clearly motivating
factors in the use of buprenorphine. Over 50% of our sample indi-
cated that buprenorphine was  useful to help them manage their
pain and over a third used it to “numb their emotional pain.” These
data reinforce the construct that substance abuse is a disorder that
rarely exists as a stand-alone entity, but often represents a coping
mechanism to treat physical and emotional issues.
Why  heroin users are more inclined to use buprenorphine
than those who  exclusively use prescription opioids is not com-
pletely clear, but may  be related to our finding that unadulterated
buprenorphine is, of course, available in the single ingredient tablet
and easily can be extracted from the more common and acces-
sible formulation, buprenorphine + naloxone, making it suitable
for injection, a route preferred by many heroin users. In con-
trast, most other opioids readily available on the street contain
acetaminophen, which addicts generally tend to avoid for safety
concerns (i.e., liver damage) and the fact that acetaminophen makes
these compounds unusable for intravenous injection (Cicero et al.,
2013). An additional factor which may favor the use of buprenor-
phine by those who  prefer or use heroin regularly is that the
immediacy and intensity of withdrawal is much greater in heroin
addicts than prescription drug users and, given the medical compli-
cations in these individuals, efforts to wean themselves off heroin
using buprenorphine may  be more intense than for prescription
opioid users. Obviously, these suggestions are speculative and more
direct studies should be carried out to examine this.
In 2011, the company marketing buprenorphine + naloxone
tablets, under the brand name Suboxone®, argued that the tablet
was inherently unsafe due to pediatric exposure and withdrew it
from distribution. As a replacement, they introduced an oral film as
a safer alternative, which perhaps not coincidentally also extended
their patent exclusivity. Although Lavonas et al. (2014) reported
that the film has reduced child exposure as reflected in poison con-
trol center calls, our data indicate it is misused as readily as the
original buprenorphine + naloxone formulation indicating that, at
least in terms of use to get high, the delivery device – film or tablets
– may  be irrelevant for those seeking buprenorphine. The larger
question is whether the addition of naloxone to the buprenorphine
in the combination product actually discouraged use to get high.
On the one hand, those who  injected it did extract the buprenor-
phine from the combination product to remove the naloxone which
apparently blunted the euphoric effect. However, oral users did not
bother to go through the steps of extraction, and apparently did get
some euphoric effect albeit one likely less in quality.
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There are limitations to our study which need to be noted. A
treatment sample may  not be representative of those using opioids
“recreationally” or of the racial and gender composition of all opioid
users. In addition, like all self-administered surveys, there are the
usual problems involving ambiguous response and the inability to
ask follow-up questions for clarification. Mitigating this problem,
to some extent, is the qualitative data provided by our interviews
with study participants which allowed much more in-depth anal-
ysis of responses and information not covered in the SKIP survey.
Finally, the absence of exposure data does not allow an estimate
of the correlation between therapeutic exposure and abuse in the
current paper, which could be useful, but this topic has been cov-
ered in our earlier work (Lavonas et al., 2014), which supports
the association of increases in misuse as a function of increases
in exposure.
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